Institution
University of the Philippines Manila
Education•Manila, Philippines•
About: University of the Philippines Manila is a education organization based out in Manila, Philippines. It is known for research contribution in the topics: Population & Medicine. The organization has 2218 authors who have published 2357 publications receiving 88781 citations. The organization is also known as: UPM.
Topics: Population, Medicine, Health care, Public health, Poison control
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Comparable immune responses and safety profiles between the two dosing schedules support the option for increased flexibility of current OCV dosing and improve implementation and delivery of cholera vaccination in endemic and epidemic outbreak scenarios.
Abstract: Background
A bivalent killed whole cell oral cholera vaccine has been found to be safe and efficacious for five years in the cholera endemic setting of Kolkata, India, when given in a two dose schedule, two weeks apart. A randomized controlled trial revealed that the immune response was not significantly increased following the second dose compared to that after the first dose. We aimed to evaluate the impact of an extended four week dosing schedule on vibriocidal response.
27 citations
••
TL;DR: Some of the experiences in overcoming newborn screening implementation challenges are reviewed and recent efforts to encourage increased newborn screening through support networking and information exchange activities in the Middle East/North Africa and in the Asia Pacific Regions are discussed.
27 citations
••
Centers for Disease Control and Prevention1, University of Jordan2, University of the Philippines Manila3, University of California, Los Angeles4, Mayo Clinic5, Merck & Co.6, University of Colorado Boulder7, Food and Drug Administration8, Michigan Department of Community Health9, University of California, San Francisco10
27 citations
••
TL;DR: A regimen of FTL-assisted delivery of TXA over a 4-week period is a safe and effective treatment option for melasma, producing significant improvement up to 3 months, and a repeat regimen every 3 months could be useful for treatment of recalcitrant melasma.
Abstract: This split-face, double-blind, randomized controlled study examines the efficacy of fractional thulium laser (FTL)-assisted delivery of topical tranexamic acid (TXA) compared with FTL alone as a treatment option for melasma. Forty-six adults with Fitzpatrick skin types III-V and recalcitrant melasma underwent four weekly treatments with fractional 1927-nm thulium laser on both sides of the face. Immediately after treatment, TXA was applied to one side of the face and normal saline solution (NSS) to the contralateral side as control under occlusion. Melanin index (MI), modified MASI (mMASI), and patients' self-assessed improvement scores were measured at baseline, 1 week, 4 weeks, and 3- and 6 months after the final treatment and were examined statistically with a paired sample t test with significance set at p ≤ 0.05. The majority of the participants (95.7%, n = 44) were female with Fitzpatrick skin type IV (82.6%) and a mean age of 48.0 ± 10.0 years. Twenty-nine individuals were able to be followed up until the 6-month assessment. Significant improvement from baseline was seen in both the MI and mMASI scores for both the TXA and control sides at 3 months, with no statistically significant difference between sides. By the 6th month, significant differences in MI and mMASI scores from baseline were still noted, except in the MI for controls. The patients' self-assessment showed similar patterns. No serious adverse events were reported for either group. A regimen of FTL-assisted delivery of TXA over a 4-week period is a safe and effective treatment option for melasma, producing significant improvement up to 3 months. Results further would suggest a repeat regimen every 3 months could be useful for treatment of recalcitrant melasma.
27 citations
••
Kwai Chung Hospital1, Hobart Corporation2, Shanghai Jiao Tong University3, Peking University4, Richmond Fellowship5, SRM University6, University of Indonesia7, University of Malaya8, University of the Philippines Manila9, Stellenbosch University10, University Hospital Complex Of Vigo11, National Cheng Kung University12, Mahidol University13, University of Melbourne14
TL;DR: A pragmatic set of recommendations for use on a day‐to‐day basis to help provide optimal care at this crucial stage of illness for patients with recent‐onset psychosis are determined.
Abstract: Providing optimal care to patients with recent-onset psychosis can improve outcomes and reduce relapse. However, there is a lack of consistency of the implementation of guidelines for such patients across the Asia-Pacific region. We determined a pragmatic set of recommendations for use on a day-to-day basis to help provide optimal care at this crucial stage of illness. The recommendations were developed over a series of meetings by an international faculty of 15 experts from the Asia-Pacific region, Europe, and South Africa. A structured search of the PubMed database was conducted. This was further developed based on the faculty's clinical experience and knowledge of the literature into 10 key aspects of optimal care for patients during the first five years of a diagnosis of a psychotic disorder, with particular relevance to the Asia-Pacific region. Several common principles emerged: adherence to antipsychotic medications is crucial; substance abuse, psychiatric and medical comorbidities should be addressed; psychosocial interventions play a pivotal role; and family members can play a vital role in overall patient care. By following these recommendations, clinicians may improve outcomes for patients with recent-onset psychosis.
26 citations
Authors
Showing all 2239 results
Name | H-index | Papers | Citations |
---|---|---|---|
Mitchel S. Berger | 120 | 641 | 53335 |
Baldomero M. Olivera | 92 | 503 | 32064 |
Adrian G. Barnett | 69 | 477 | 16536 |
Martin L. Hibberd | 69 | 247 | 17482 |
Peter Proksch | 69 | 693 | 20980 |
A. Douglas Kinghorn | 64 | 405 | 23180 |
Carl Abelardo T. Antonio | 60 | 106 | 66867 |
Carlos A Castañeda-Orjuela | 58 | 137 | 74960 |
Johannes J. Rasker | 53 | 281 | 9870 |
Paiboon Sithithaworn | 48 | 240 | 8225 |
Antonio L. Dans | 46 | 114 | 15661 |
David R. Hillyard | 46 | 130 | 8296 |
Lorraine S. Evangelista | 44 | 159 | 6001 |
Lourdes J. Cruz | 43 | 58 | 8079 |
Prashant Kapoor | 41 | 415 | 7578 |